Drug Approval | December 10, 2021
China approves Brii Bio’s antibody combination to neutralise Covid-19
Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA
Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA
Saroglitazar Mg is an investigational compound in the USA, and is yet to be approved by the U.S. Food & Drug Administration (USFDA) or European Medicines Agency (EMA)
The interim results of Phase 3 clinical trials conducted by CanSinoBIO demonstrated that Convidecia has an efficacy of 95.47% at preventing severe disease 14 days after single-dose vaccination.
The platform’s technology works as a compression algorithm for molecular testing
Lupin Diagnostics will provide a comprehensive range of diagnostic tests. These include molecular diagnostics, cytogenetics, flow cytometry, microbiology, serology, histopathology and cytology, haematology, immunology, amongst others.
Gland Pharma believes that they are amongst one of the first to file for this product and may be eligible for 180 days of generic drug exclusivity
Whipple procedure is a very complex operation, mainly performed to remove pancreatic cancer
The license agreement grants Dr. Reddy's the exclusive rights to commercialize the proposed biosimilar in select countries in Latin America and Southeast Asia
The Uteshiya facility, licensed by Healthium, will exclusively manufacture Healthium’s arthroscopy portfolio, including patented products in India and U.S.
Philips Patient Monitors IntelliVue MX750 and IntelliVue MX850 pair with advanced software and services to offer clinical decision support, continuous, scalable patient management and enhanced infection control
Subscribe To Our Newsletter & Stay Updated
